一、监事会会议召开情况 2025 年 8 月 15 日，奕瑞电子科技集团股份有限公司（以下简称"公司"） 以现场及通讯方式召开了第三届监事会第十四次会议（以下简称"本次会议"）， 会议通知已于 2025 年 8 月 12 日以电子邮件形式发出。本次会议由监事会主席丰 华先生主持，会议应出席监事 3 人，实际出席并表决的监事 3 人。本次会议的召 开及表决程序符合《中华人民共和国公司法》（以下简称"《公司法》"）等相关法 律、法规以及《公司章程》的有关规定。 二、监事会会议审议情况 （一） 审议通过《关于调整向特定对象发行 A 股股票发行数量上限的议案》 监事会认为：同意公司根据《公司法》《中华人民共和国证券法》《上市公司 证券发行注册管理办法》等法律法规和规范性文件的规定，结合公司自身实际情 况，对公司 2024 年度向特定对象发行 A 股股票的发行数量上限进行调整。具体 如下： 鉴于公司实施 2024 年年度权益分派、可转债转股以及股权激励限制性股票 归属事项，公司总股本发生变化，故公司 2024 年度向特定对象发行 A 股股票的 发行数量上限由不超过 21,418,292 股（含本数）调整为不超过 30, ...

[Definitions](index=4&type=section&id=Section%201%20Definitions) This chapter defines key terms and company abbreviations, covering X-ray technology, components, medical imaging, and subsidiaries, essential for report comprehension - This chapter defines professional terms and company entity abbreviations, covering X-ray technology, key components, medical imaging equipment, industry standards, and company subsidiaries, providing a basis for understanding the report content[11](index=11&type=chunk)[12](index=12&type=chunk)[13](index=13&type=chunk) [Company Profile and Key Financial Indicators](index=10&type=section&id=Section%202%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section provides the company's basic information, key financial data, and details on non-recurring gains and losses for the reporting period [Basic Company Information](index=10&type=section&id=I.%20Basic%20Company%20Information) This chapter provides the company's basic business information, including names, legal representative, and addresses, noting a change in registered address during the period - The company's full name is **iRay Technology Group Co., Ltd.**, with Tieer Gu as its legal representative[18](index=18&type=chunk) - In February 2025, the company's registered address changed from 'Room 202, Building 9, No. 590 Ruiqing Road, Pudong New Area, Shanghai' to 'No. 999 Huanqiao Road, Pudong New Area, Shanghai'[18](index=18&type=chunk) [Key Accounting Data and Financial Indicators](index=11&type=section&id=VI.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) During the reporting period, the company's operating revenue grew by **3.94%**, net profit attributable to shareholders increased by **8.82%**, and net cash flow from operating activities surged by **340.20%** due to increased customer deposits and sales collections, while non-recurring adjusted net profit decreased by **2.11%** Key Accounting Data | Key Accounting Data | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | RMB 1,066,611,820.18 | RMB 1,026,151,704.71 | 3.94% | | Net Profit Attributable to Shareholders of Listed Company | RMB 334,567,467.70 | RMB 307,441,804.39 | 8.82% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Items) | RMB 328,308,023.36 | RMB 335,380,730.02 | -2.11% | | Net Cash Flow from Operating Activities | RMB 817,732,776.49 | RMB 185,763,701.58 | 340.20% | | Total Assets (End of Reporting Period) | RMB 9,804,974,935.43 | RMB 9,083,006,463.92 | 7.95% | Key Financial Indicators | Key Financial Indicators | Current Period (Jan-Jun) | Prior Period | YoY Change (%) | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (RMB/share) | 1.67 | 1.54 | 8.44% | | Diluted Earnings Per Share (RMB/share) | 1.66 | 1.51 | 9.93% | | Weighted Average Return on Net Assets (%) | 6.93% | 6.92% | Increase 0.01 percentage points | | R&D Investment as Percentage of Operating Revenue (%) | 14.46% | 14.92% | Decrease 0.46 percentage points | [Non-Recurring Gains and Losses Items and Amounts](index=11&type=section&id=VIII.%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) During the reporting period, the company's total non-recurring gains and losses amounted to **RMB 6.2594 million**, primarily comprising government subsidies, fair value changes in financial assets, and other non-operating income and expenses Non-Recurring Gains and Losses Items | Non-Recurring Gains and Losses Items | Amount (RMB) | | :--- | :--- | | Government Subsidies Included in Current Profit and Loss | 7,408,591.20 | | Gains and Losses from Fair Value Changes and Disposal of Financial Assets and Liabilities | -1,895,459.42 | | Other Non-Operating Income and Expenses | 2,104,372.66 | | Income Tax Impact | -321,313.05 | | Impact on Minority Interests (After Tax) | -1,036,441.02 | | **Total** | **6,259,444.34** | [Management Discussion and Analysis](index=13&type=section&id=Section%203%20Management%20Discussion%20and%20Analysis) This section provides an in-depth analysis of the company's industry, operational performance, core competencies, risk factors, and key financial and operational highlights during the reporting period [Industry and Main Business Overview](index=13&type=section&id=I.%20Explanation%20of%20Industry%20and%20Main%20Business%20During%20the%20Reporting%20Period) The company is a mid-stream supplier of X-ray imaging equipment core components and solutions, specializing in digital X-ray detectors, high-voltage generators, and X-ray tubes, with a leading global market share in digital X-ray detectors and expanding into other core components to build vertical integration advantages, while the industry trends towards broader applications, supply chain shifts to China, and dynamic and 3D imaging technologies - The company operates in the mid-stream of the X-ray imaging equipment industry, primarily engaged in the R&D, production, and sales of core components such as digital X-ray detectors, high-voltage generators, and X-ray tubes[31](index=31&type=chunk)[33](index=33&type=chunk) Global X-ray Core Component Market Size Forecast (by Sales Revenue) | X-ray Core Component Global Market Size Forecast (by Sales Revenue) | 2021/2023 | 2030 Forecast | CAGR | | :--- | :--- | :--- | :--- | | Digital X-ray Detectors | 2.28 billion USD (2021) | 5.03 billion USD | 9.3% (2022-2030) | | High-Voltage Generators | 0.79 billion USD (2021) | 1.30 billion USD | 6.3% (2022-2030) | | X-ray Tubes | 4.26 billion USD (2023) | 9.53 billion USD | 12.18% (2023-2030) | | Combined X-ray Sources | 2.39 billion USD (2021) | 7.41 billion USD | 14.3% (2022-2030) | - The company holds a leading global market share in digital X-ray detectors, reaching **19.83%** in 2024, and ranks first in the domestic market[55](index=55&type=chunk) - The company's product lines cover both medical (general radiography, dental, mammography, radiotherapy) and industrial (non-destructive testing, security inspection) fields, mastering four major sensor technologies: amorphous silicon, IGZO, CMOS, and flexible substrates[64](index=64&type=chunk) [Discussion and Analysis of Operations](index=26&type=section&id=II.%20Discussion%20and%20Analysis%20of%20Operations) In the first half of 2025, the company advanced high-quality development amidst a complex macro environment, making progress in R&D, market expansion, supply chain optimization, financial internal control, and human resource system development, with R&D investment reaching **RMB 154 million** (14.46% of revenue), new core components and solutions business growing over **50%**, and the global '1 headquarters + 6 bases' layout accelerating - During the reporting period, the company's R&D investment was **RMB 154 million**, accounting for **14.46%** of operating revenue, with **70** new IP authorizations, including **32** invention patents[85](index=85&type=chunk) - In market expansion, new core components and solutions businesses, such as high-voltage generators and combined X-ray sources, achieved significant growth, with a year-on-year increase of over **50%**[89](index=89&type=chunk) - Regarding the supply chain, the company's global '1 headquarters + 6 bases' layout is accelerating, with **6** factory locations worldwide, enhancing production and operational efficiency through digital means[90](index=90&type=chunk)[91](index=91&type=chunk) [Analysis of Core Competencies](index=28&type=section&id=III.%20Analysis%20of%20Core%20Competencies%20During%20the%20Reporting%20Period) The company's core competencies are primarily in five areas: technological advantages (mastering various X-ray core component technologies), talent advantages (a high-caliber R&D team of **633**), customer resource advantages (stable collaborations with renowned domestic and international manufacturers), product quality advantages (multiple international quality system certifications), and customer service advantages (a global service network) - Technological Advantage: The company is one of the few global manufacturers of digital X-ray detectors mastering all major core technologies, including TFT, CMOS sensors, scintillator materials, and readout chips, having established an X-ray core technology matrix spanning multiple product areas[94](index=94&type=chunk) - Talent Advantage: As of the end of the reporting period, the company had **633** R&D personnel, accounting for **30.24%** of the total workforce, with **33.97%** holding master's degrees or higher[95](index=95&type=chunk)[119](index=119&type=chunk) - Customer Resource Advantage: The company has established strong, high-stickiness cooperative relationships with renowned domestic and international manufacturers such as Konica, Carestream, GE Healthcare, Siemens, Philips, United Imaging Healthcare, and CATL[97](index=97&type=chunk)[98](index=98&type=chunk) [Risk Factors](index=38&type=section&id=IV.%20Risk%20Factors) The company faces five main categories of risks: core competency risks (new technology development, technology substitution, talent loss), operational risks (raw material supply, intellectual property, expansion management), financial risks (accounts receivable, gross margin fluctuations, tax policies, exchange rates, inventory, debt ratio), market risks (industry prosperity, product price decline, market competition), and macroeconomic environment risks (trade friction, industrial policy changes) - Core Competency Risk: Rapid technological iteration in the industry poses a risk of weakened market competitiveness if the company fails to launch innovative products promptly, alongside high R&D investment and the risk of project failure or uncompetitive new products[120](index=120&type=chunk) - Financial Risk: Accounts receivable book value at the end of the reporting period was **RMB 835 million**, accounting for **8.52%** of total assets and growing rapidly; the asset-liability ratio was **50.54%**, with high interest-bearing debt potentially increasing financial expenses and risks[131](index=131&type=chunk)[137](index=137&type=chunk) - Construction in Progress Risk: As of the end of the reporting period, construction in progress amounted to **RMB 2.753 billion**, which upon completion will significantly increase depreciation and amortization, potentially impacting operating performance if revenue falls short of expectations[129](index=129&type=chunk) - Market Risk: Intensified industry competition and localization efforts may lead to continuous product price declines, posing risks to the company's gross margin and profitability if cost control or product upgrades fail to keep pace[139](index=139&type=chunk)[140](index=140&type=chunk) [Key Operating Conditions](index=42&type=section&id=V.%20Key%20Operating%20Conditions%20During%20the%20Reporting%20Period) This chapter provides a detailed analysis of the company's financial status during the reporting period, highlighting a **340.20%** increase in net cash flow from operating activities due to customer performance deposits and increased sales collections, a **48.77%** decrease in net cash outflow from investing activities due to lower payments for construction and equipment, and a shift from positive to negative net cash flow from financing activities primarily due to significant long-term borrowings in the prior period and repayment of short-term borrowings in the current period Cash Flow Statement Key Items | Item | Current Period Amount (RMB) | Prior Period Amount (RMB) | Change (%) | Explanation of Change | | :--- | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 817,732,776.49 | 185,763,701.58 | 340.20 | Primarily due to receipt of customer performance deposits and increased sales collections | | Net Cash Flow from Investing Activities | -412,267,548.59 | -804,725,510.10 | 48.77 | Primarily due to lower payments for construction and equipment purchases compared to the prior period | | Net Cash Flow from Financing Activities | -259,815,246.03 | 596,530,542.04 | -143.55 | Primarily due to a larger increase in long-term borrowings in the prior period and repayment of some short-term borrowings in the current period | Asset/Liability Key Items | Asset/Liability Item | Amount at End of Current Period (RMB) | Amount at End of Prior Period (RMB) | Change (%) | Explanation | | :--- | :--- | :--- | :--- | :--- | | Other Payables | 578,892,691.13 | 26,734,329.13 | 2,065.35 | Due to receipt of performance deposits | | Fixed Assets | 1,950,965,264.11 | 1,440,622,330.63 | 35.43 | Due to transfer of construction in progress to fixed assets upon reaching intended usable state | | Long-term Equity Investments | 118,421,062.29 | 72,313,374.68 | 63.76 | Due to new external investments | [Corporate Governance, Environment, and Society](index=49&type=section&id=Section%204%20Corporate%20Governance,%2C%20Environment%2C%20and%20Society) This section details changes in the company's directors, supervisors, senior management, and core technical personnel, along with the proposed profit distribution plan for the reporting period [Changes in Directors, Supervisors, Senior Management, and Core Technical Personnel](index=49&type=section&id=I.%20Changes%20in%20Company%20Directors,%20Supervisors,%20Senior%20Management,%20and%20Core%20Technical%20Personnel) During the reporting period, there were no changes in the company's directors, supervisors, senior management, or core technical personnel, whose identification criteria are primarily based on their contributions to core technology R&D, project leadership, intellectual property, and industry experience - There were no changes in the company's directors, supervisors, senior management, or core technical personnel during the reporting period[172](index=172&type=chunk) [Profit Distribution Plan](index=49&type=section&id=II.%20Profit%20Distribution%20or%20Capital%20Reserve%20to%20Share%20Capital%20Increase%20Plan) The company has no proposed profit distribution or capital reserve to share capital increase plan for the first half of 2025 - The proposed profit distribution and capital reserve to share capital increase plan for the first half of 2025 is **'No'**[173](index=173&type=chunk) [Significant Matters](index=51&type=section&id=Section%205%20Significant%20Matters) This section covers the fulfillment of commitments, major litigation, significant related-party transactions, and the progress of raised funds utilization during the reporting period [Fulfillment of Commitments](index=51&type=section&id=I.%20Fulfillment%20of%20Commitments) During the reporting period, the company's actual controllers, shareholders, directors, supervisors, and senior management strictly fulfilled all commitments made during initial public offerings, refinancing, and equity incentive activities, including share lock-ups, avoidance of horizontal competition, and regulation of related-party transactions, with no breaches observed - The company's actual controllers, shareholders, directors, supervisors, and other related parties strictly fulfilled all commitments, including share lock-ups, avoidance of horizontal competition, and regulation of related-party transactions, during the reporting period[177](index=177&type=chunk) [Major Litigation and Arbitration Matters](index=59&type=section&id=VII.%20Major%20Litigation%20and%20Arbitration%20Matters) The lawsuit involving the company's Korean subsidiary (iRay Korea) and its representative director has concluded, with the Korean prosecution not appealing the second instance's acquittal, which became effective on April 17, 2025 - The second instance court's acquittal in the lawsuit against iRay Korea and its representative director became effective on **April 17, 2025**, concluding the case[210](index=210&type=chunk) [Significant Related-Party Transactions](index=60&type=section&id=X.%20Significant%20Related-Party%20Transactions) During the reporting period, the company engaged in several related-party transactions related to daily operations, including sales, purchases, leases, and performance deposits, with notable transactions being sales to SeeYa Technology and collection of significant performance deposits, purchases from E-ray Co., Ltd., and a joint external investment with related parties in Haining Kaitu Semiconductor Co., Ltd Related-Party Transaction Details | Related-Party Transaction Type | Related Party | Cumulative Amount for 2025 (RMB in ten thousands) | | :--- | :--- | :--- | | Sales of Products to Related Parties | Shenzhen Phison Technology Co., Ltd. | 2,020.64 | | Collection of Performance Deposits | SeeYa Technology Co., Ltd. | 56,552.94 | | Purchases of Goods from Related Parties | E-ray Co., Ltd. | 2,745.65 | - The company, through its wholly-owned subsidiary iRay Hefei, invested **RMB 20 million** in Haining Kaitu Semiconductor Co., Ltd., acquiring an **18.18%** stake, which constitutes a joint investment with a related party[214](index=214&type=chunk) [Explanation of Progress in Use of Raised Funds](index=63&type=section&id=XII.%20Explanation%20of%20Progress%20in%20Use%20of%20Raised%20Funds) The company provided an explanation of the use of proceeds from its initial public offering and convertible bond issuance, with cumulative investment progress at **92.55%** for IPO proceeds and **87.55%** for convertible bond proceeds as of the end of the reporting period, and some projects, such as the 'New Detector and Scintillator Material Industrialization Project,' having applied for extensions Raised Funds Utilization Progress | Source of Raised Funds | Net Proceeds (RMB in ten thousands) | Cumulative Investment at End of Reporting Period (RMB in ten thousands) | Cumulative Investment Progress (%) | | :--- | :--- | :--- | :--- | | Initial Public Offering (IPO) | 198,616.94 | 183,821.22 | 92.55% | | Issuance of Convertible Bonds | 142,131.35 | 124,434.31 | 87.55% | [Share Changes and Shareholder Information](index=66&type=section&id=Section%206%20Share%20Changes%20and%20Shareholder%20Information) This section provides an overview of the company's share capital changes and detailed shareholder information, including the top ten shareholders [Share Capital Changes](index=66&type=section&id=I.%20Share%20Capital%20Changes) During the reporting period, the company's total share capital increased from **143 million** shares to **200 million** shares, primarily due to the implementation of the 2024 annual capital reserve to share capital increase plan (0.4 shares per share) and a small number of 'iRay Convertible Bonds' converting into company shares - The company's total share capital increased by **57,155,546** shares due to the capital reserve to share capital increase plan (0.4 shares per share)[227](index=227&type=chunk)[228](index=228&type=chunk) - During the reporting period, a cumulative total of **6** 'iRay Convertible Bonds' were converted into shares[228](index=228&type=chunk) [Shareholder Information](index=67&type=section&id=II.%20Shareholder%20Information) As of the end of the reporting period, the company had **6,990** common shareholders, with Shanghai Yiyuan Herui Investment Consulting Co., Ltd. being the largest shareholder holding **16.33%**, and the top ten shareholders largely comprising company-affiliated investment platforms, employee stock ownership platforms, and institutional investors Top Shareholders | Shareholder Name | Shares Held at Period End (shares) | Percentage (%) | | :--- | :--- | :--- | | Shanghai Yiyuan Herui Investment Consulting Co., Ltd. | 32,696,549 | 16.33 | | Tianjin Sequoia Juye Equity Investment Partnership | 11,785,883 | 5.89 | | Hainan Heyi Investment Co., Ltd. | 11,721,318 | 5.85 | | Shanghai Changze Management Consulting Partnership | 10,668,085 | 5.33 | | Beijing Sequoia Xinyuan Equity Investment Center | 5,547,286 | 2.77 | [Bond-Related Information](index=71&type=section&id=Section%207%20Bond-Related%20Information) This section provides details on the company's convertible bonds, including issuance terms, conversion status, and adjustments to the conversion price [Convertible Corporate Bonds](index=71&type=section&id=II.%20Convertible%20Corporate%20Bonds) The company issued **RMB 1.435 billion** in convertible corporate bonds, 'iRay Convertible Bonds' (code 118025), in October 2022; as of the end of the reporting period, there were **5,342** bondholders, with **99.07%** of the bonds yet to be converted, and the conversion price was adjusted to **RMB 115.50/share** on June 19, 2025, due to the 2024 profit distribution and capital reserve to share capital increase plan - The company's 'iRay Convertible Bonds' have a total value of **RMB 1.435 billion**, a 6-year term, and were listed for trading on **November 18, 2022**[239](index=239&type=chunk) Convertible Bond Status | Metric | Value | | :--- | :--- | | Amount Converted in Reporting Period | RMB 1,000 | | Cumulative Shares Converted | 57,686 shares | | Unconverted Bond Amount | RMB 1,421,735,000 | | Percentage of Unconverted Bonds to Total Issuance | 99.0749% | - Due to the implementation of the 2024 annual profit distribution and capital reserve to share capital increase plan, the conversion price was adjusted from **RMB 162.64/share** to **RMB 115.50/share** on **June 19, 2025**[246](index=246&type=chunk) [Financial Report](index=75&type=section&id=Section%208%20Financial%20Report) This section presents the company's unaudited financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in owner's equity, along with significant accounting policies and detailed notes to the consolidated financial statements [Financial Statements](index=75&type=section&id=II.%20Financial%20Statements) This chapter provides the company's unaudited 2025 semi-annual consolidated and parent company financial statements, including the balance sheet, income statement, cash flow statement, and statement of changes in owner's equity, reflecting the company's financial position, operating results, and cash flows during the reporting period Key Items from Consolidated Balance Sheet (2025-06-30) | Key Items from Consolidated Balance Sheet (2025-06-30) | Amount (RMB) | | :--- | :--- | | Total Assets | 9,804,974,935.43 | | Total Liabilities | 4,955,562,542.36 | | Total Equity Attributable to Parent Company Owners | 4,851,035,642.02 | Key Items from Consolidated Income Statement (Jan-Jun 2025) | Key Items from Consolidated Income Statement (Jan-Jun 2025) | Amount (RMB) | | :--- | :--- | | Total Operating Revenue | 1,066,611,820.18 | | Total Profit | 366,795,900.81 | | Net Profit | 324,998,931.52 | | Net Profit Attributable to Parent Company Shareholders | 334,567,467.70 | [Significant Accounting Policies and Estimates](index=91&type=section&id=V.%20Significant%20Accounting%20Policies%20and%20Estimates) This chapter elaborates on the company's fundamental accounting principles, including enterprise accounting standards, accounting period, and functional currency, used for financial statement preparation, and explains accounting policies and estimates for key items such as financial instruments, inventories, long-term equity investments, fixed assets, intangible assets, revenue recognition, and government grants, noting no significant changes in accounting policies during the reporting period - Financial statements are prepared on a going concern basis, adhering to Chinese Enterprise Accounting Standards[281](index=281&type=chunk)[282](index=282&type=chunk) - Revenue Recognition Policy: The company recognizes revenue when customers obtain control of the related goods or services, with domestic sales recognized upon customer receipt and international sales upon completion of customs declaration[352](index=352&type=chunk)[354](index=354&type=chunk) - Financial Instrument Impairment: The company applies impairment accounting for financial assets measured at amortized cost based on expected credit losses, and for accounts receivable and contract assets, loss provisions are always measured at the amount of expected credit losses over their entire lifetime[312](index=312&type=chunk) [Notes to Consolidated Financial Statement Items](index=112&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This chapter provides detailed notes and explanations for major items in the consolidated financial statements, including the composition, changes, and related details of monetary funds, accounts receivable, inventories, fixed assets, construction in progress, short-term borrowings, bonds payable, share capital, capital reserves, and operating revenue and costs, offering essential supplementary information for understanding the financial statement data - The top five accounts receivable balances at period-end collectively accounted for **23.13%** of the total, with bad debt provisions calculated based on individual and aging portfolio methods[397](index=397&type=chunk)[403](index=403&type=chunk) - The balance of construction in progress at period-end was **RMB 2.753 billion**, primarily for the 'New Detector and Scintillator Material Industrialization Project' and the 'Digital X-ray Detector Key Technology R&D and Comprehensive Innovation Base Construction Project'[454](index=454&type=chunk) - Other payables significantly increased to **RMB 579 million** at period-end, primarily due to the receipt of **RMB 567 million** in deposits and guarantees[499](index=499&type=chunk)

重要内容提示： | 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-054 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 关于调整向特定对象发行A股股票发行数量上限的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 因奕瑞电子科技集团股份有限公司（以下简称"公司"）实施 2024 年年度 权益分派、可转债转股以及股权激励限制性股票归属事项，公司总股本发生变化， 故公司 2024 年度向特定对象发行 A 股股票的发行数量上限由不超过 21,418,292 股（含本数）调整为不超过 30,032,755 股（含本数）。 一、本次向特定对象发行 A 股股票事项情况 公司于 2024 年 4 月 28 日召开第三届董事会第四次会议以及第三届监事会第 四次会议，于 2024 年 5 月 24 日召开 2023 年年度股东大会，会议审议通过了《关 于公司 2024 年度向特定对象发行 A 股股票方案的议案》等议案，具体 ...

中国国际金融股份有限公司 关于奕瑞电子科技集团股份有限公司使用自有资金支付募投项目 所需资金并以募集资金等额置换的核查意见 中国国际金融股份有限公司（以下简称"保荐机构"）作为奕瑞电子科技集团股份有 限公司（以下简称"奕瑞科技"或"公司"）的保荐机构，根据《证券发行上市保荐业务管 理办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、行政法 规、部门规章及业务规则的要求，对奕瑞电子科技集团股份有限公司本次使用暂时闲置 募集资金进行现金管理的事项进行了认真、审慎核查，具体情况如下： 一、募集资金基本情况 经中国证监会《关于同意上海奕瑞光电子科技股份有限公司向不特定对象发行可转 债注册的批复》（证监许可[2022]2167 号）同意注册，公司向不特定对象共计发行 14,350,100 张可转换公司债券，每张面值为人民币 100 元，按面值发行。本次发行可转 债募集资金总额为人民币 143,501.00 万元；扣除发行费用（不含增值税）人民币 1,369.65 万元后，募集资金净额为人民币 142,131.35 万元， ...

关于奕瑞电子科技集团股份有限公司 使用暂时闲置募集资金进行现金管理事项的核查意见 中国国际金融股份有限公司 中国国际金融股份有限公司（以下简称"保荐机构"）作为奕瑞电子科技集团股份有 限公司（以下简称"奕瑞科技"或"公司"）的保荐机构，根据《证券发行上市保荐业务管 理办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、行政法 规、部门规章及业务规则的要求，对奕瑞电子科技集团股份有限公司本次使用暂时闲置 募集资金进行现金管理的事项进行了认真、审慎核查，具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 1、2020 年公司首次公开发行股票募集资金情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2020 年 8 月 18 日出 具的《关于同意上海奕瑞光电子科技股份有限公司首次公开发行股票注册的批复》（证 监许可[2020]1823 号），同意公司首次公开发行股票的注册申请。 公司首次公开发行人民币普通股（A 股）1,820.00 万股，每股发行价格为人民币 119.60 元，募集 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-055 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 2025 年半年度募集资金存放与实际使用情况的专项 报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》和《上海证券交易所科创板股票上市规则》等有 关规定，现将奕瑞电子科技集团股份有限公司（以下简称"公司"）2025 年半 年度募集资金存放与实际使用情况报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 1、2020 年公司首次公开发行股票募集资金情况 经中国证券监督管理委员会出具的《关于同意上海奕瑞光电子科技股份有限 公司首次公开发行股票注册的批复》（证监许可[2020]1823 号）同意，公司首次 公开发行人民币普通股（A 股）1,820 万股，每股发行价格人民币 119.60 元，募 ...

奕瑞科技8月15日晚间公告，公司上半年实现营业收入10.67亿元，同比增长3.94%；归属于上市公司股 东的净利润3.35亿元，上年同期3.07亿元，同比增长8.82%；基本每股收益1.67元。经营活动产生的现金 流量净额增加，主要系收到客户支付履约保证金，以及销售回款增加所致。 ...

Core Viewpoint - Yirui Technology's stock closed at 91.98 yuan, down 5.22%, with a rolling PE ratio of 39.27 times and a total market value of 18.416 billion yuan [1] Company Summary - Yirui Technology specializes in the research, production, sales, and service of digital X-ray detectors, high-voltage generators, combination ray sources, and tubes [1] - The main products include the universal series, dental series, mammography series, radiotherapy series, industrial series, high-voltage generators, and combination ray sources [1] - For Q1 2025, the company reported revenue of 482 million yuan, a year-on-year decrease of 1.92%, and a net profit of 143 million yuan, a year-on-year increase of 2.74%, with a gross profit margin of 48.92% [1] Industry Summary - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, placing Yirui Technology at the 77th position in the industry ranking [1] - The industry average market value is 11.792 billion yuan, while the median market value is 5.679 billion yuan [2] - Other companies in the industry have varying PE ratios, with the lowest being 11.18 times for Jiuan Medical and the highest being 20.62 times for Antu Biology [2]

Market Overview - The market continues its upward trend with all three major indices reaching new highs for the year, with the Shanghai Composite Index achieving a seven-day winning streak and peaking at 3669.04 points [1] - A-shares saw a total trading volume of 1.91 trillion yuan, marking a significant increase in market activity over the past two days [1] Technology Sector - The technology growth sector is thriving, with significant gains in various ETFs, particularly those focused on AI and hard technology [1] - The AI sector is highlighted as a key focus, with stocks like Cambricon Technologies hitting the daily limit and achieving historical highs in trading volume and price [1] - The Huabao Entrepreneurial AI ETF (159363) surged by 3.03%, reaching a new listing high, reflecting strong investor interest [1][4] Financial Sector - The financial sector is also performing well, with brokerage stocks leading the charge, as evidenced by Guosheng Financial Holdings hitting the daily limit [2] - The top-performing brokerage ETF (512000) experienced high-frequency premiums, indicating strong market confidence [2] - Bank stocks are recovering, with Agricultural Bank of China achieving new highs for six consecutive days [2] AI and Cloud Computing - Positive news in the AI sector includes Huawei's announcement of a breakthrough in AI inference technology, which is expected to accelerate AI application growth [6][13] - The capital expenditure of major cloud companies is projected to exceed $330 billion by 2025, indicating robust growth in the AI and cloud computing sectors [6] - The entrepreneurial AI index has seen a cumulative increase of nearly 35% this year, outperforming other AI indices [6] Investment Opportunities - Analysts recommend focusing on the "AI main line" investment opportunities, particularly in the AI application and computing power sectors [8] - The domestic semiconductor industry is expected to benefit from increased demand for AI chips, driven by the need for domestic alternatives amid rising geopolitical tensions [13][14] - The medical sector is also gaining traction, with significant interest in brain-computer interface technologies and related stocks [15][17] ETF Performance - The Huabao Entrepreneurial AI ETF (159363) has become the largest in its category, with a trading volume of 2.67 billion yuan, reflecting high market activity [4][18] - The Huabao Sci-Tech AI ETF (589520) also performed well, with a peak increase of 3.12% during trading [9][14] Key Developments - The upcoming release of DeepSeek-R2 is generating excitement in the market, with expectations of significant advancements in AI capabilities [11] - The Ministry of Industry and Information Technology has outlined plans to promote the development of brain-computer interface technologies, indicating a growing focus on this innovative sector [17]

资金面上看，今日牙科医疗概念板块获主力资金净流出4.75亿元，其中，8股获主力资金净流入，净流 入资金居首的是皓宸医疗，今日主力资金净流入1.12亿元，净流入资金居前的还有美年健康、奕瑞科 技、宏盛股份等，主力资金分别净流入4540.95万元、4527.53万元、2863.59万元。 资金流入比率方面，皓宸医疗、美年健康、宏盛股份等流入比率居前，主力资金净流入率分别为 34.57%、11.58%、11.22%。（数据宝） 牙科医疗概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 002622 | 皓宸医 疗 | 9.88 | 11.13 | 11196.57 | 34.57 | | 002044 | 美年健 康 | 0.19 | 1.92 | 4540.95 | 11.58 | | 688301 | 奕瑞科 技 | 4.81 | 2.37 | 4527.53 | 10.01 | | 603090 | 宏盛股 ...